Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma. (2022)

First Author: Badodi S
Attributed to:  A BMI1/CHD7 signature in medulloblastoma with poor prognosis. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/neuonc/noac052

PubMed Identifier: 35213723

Publication URI: http://europepmc.org/abstract/MED/35213723

Type: Journal Article/Review

Volume: 24

Parent Publication: Neuro-oncology

Issue: 8

ISSN: 1522-8517